Importantly, CCL20 is known to recruit pathogenic lymphocytes by acting on its receptor CCR6 in colitis and molecules targeting the CCL20/CCR6 axis are already in clinical development (Allodi et al., 2023). The gene discussed is CCR6; the disease is colitis.